Joerg Mahlich (Jörg Mahlich, Jӧrg Mahlich, J Mahlich)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 31

Top Topics

Patients With Inflammatory Bowel Disease

Rheumatoid Arthritis

Top Venues

Clinical drug investigation

Healthcare (Basel, Switzerland)

Crohn's & colitis 360

This page only lists publications with an associated author ORCID identifier.

Publications

Yoji Inoue, Shinichi Oka, Seiji Yokoyama, Koichi Hasegawa, Joerg Mahlich, Ulrike Schaede, Noriyuki Habuka, Yoko Murata
Medication Adherence of People Living with HIV in Japan-A Cross-Sectional Study. Healthcare (Basel, Switzerland) 11 (4) (2023)
Peter Borchmann, Jan-Michel Heger, Joerg Mahlich, Michael S Papadimitrious, Sybille Riou, Barbara Werner
Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database. Journal of cancer research and clinical oncology (2023)
Yoji Inoue, Shinichi Oka, Seiji Yokoyama, Koichi Hasegawa, Joerg Mahlich, Ulrike Schaede, Noriyuki Habuka, Yoko Murata
Medication Adherence of People Living with HIV in Japan-A Cross-Sectional Study. Healthcare (Basel, Switzerland) 11 (4) (2023)
Yoji Inoue, Shinichi Oka, Seiji Yokoyama, Koichi Hasegawa, Joerg Mahlich, Ulrike Schaede, Noriyuki Habuka, Yoko Murata
Medication Adherence of People Living with HIV in Japan-A Cross-Sectional Study. Healthcare (Basel, Switzerland) 11 (4) (2023)
Christof Scheid, Robert Kudernatsch, Marie Eckart, Chiara Feig, Vincent Straub, Berit Libutzki, Joerg Mahlich
Treatment Pathways and Health Outcomes of German Patients with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Health Claims Data Analysis. Drugs - real world outcomes 9 (4) (2022)
Peter Borchmann, Jan-Michel Heger, Joerg Mahlich, Michael S Papadimitrious, Sybille Riou, Barbara Werner
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis. Oncology and therapy (2022)
Arnold Käffer, Joerg Mahlich
Culture and COVID-19-related mortality: a cross-sectional study of 50 countries. Journal of public health policy 43 (3) (2022)
Joerg Mahlich, Melanie May, Chiara Feig, Vincent Straub, Renate Schmelz
Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. Crohn's & colitis 360 3 (2) (2021)
Joerg Mahlich, Arne Bartol, Srirangan Dheban
Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health economics review 11 (1) (2021)
Joerg Mahlich, Srirangan Dheban
Bright line or lottery? On significance and value in medical decision making. Journal of market access & health policy 9 (1) (2021)
Joerg Mahlich, Melanie May, Chiara Feig, Vincent Straub, Renate Schmelz
Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. Crohn's & colitis 360 3 (2) (2021)
Celine Miyazaki, Rosarin Sruamsiri, Joerg Mahlich, Wonjoo Jung
Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study. Journal of medical economics 23 (7) (2020)
Celine Miyazaki, Rosarin Sruamsiri, Joerg Mahlich, Wonjoo Jung
Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study. PloS one 15 (5) (2020)
Matthias Augustin, Daniel Wirth, Joerg Mahlich, Alicia N Pepper, Cheryl Druchok
Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. The Journal of dermatological treatment (2020)
Joerg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer, Claus Wolff-Menzler
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics. Clinical drug investigation 41 (1) (2020)
Joerg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer, Claus Wolff-Menzler
Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clinical drug investigation 40 (4) (2020)
Joerg Mahlich, Rosarin Sruamsiri
Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach. International journal for equity in health 18 (1) (2019)
Yusuke Nakamura, Isao Shibata, Joerg Mahlich
Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital. Neurology and therapy 8 (2) (2019)
Joerg Mahlich, Ulrike Schaede, Rosarin Sruamsiri
Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New "Preference Fit" Framework for Treatment Assessment. Rheumatology and therapy 6 (2) (2019)
Joerg Mahlich, Aranzazu Alba, Laila El Hadad, Marie-Kristin Leisten, Wiebke K Peitsch
Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis. Advances in therapy 36 (7) (2019)
Joerg Mahlich, Akiko Tsubota, Keiichiro Imanaka, Kentaro Enjo
Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis. Current medical research and opinion 34 (10) (2018)
Florent Guelfucci, Yuko Kaneko, Joerg Mahlich, Rosarin Sruamsiri
Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data. Rheumatology and therapy 5 (1) (2018)
Rosarin Sruamsiri, Kosuke Iwasaki, Wentao Tang, Joerg Mahlich
Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC dermatology 18 (1) (2018)
Stephane Cheung, Yukinobu Hamuro, Joerg Mahlich, Masahiko Nakayama, Akiko Tsubota
Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data. PloS one 13 (4) (2018)
Joerg Mahlich, Katsuyoshi Matsuoka, Rosarin Sruamsiri
Biologic treatment of Japanese patients with inflammatory bowel disease. BMC gastroenterology 18 (1) (2018)
Joerg Mahlich, Piyameth Dilokthornsakul, Rosarin Sruamsiri, Nathorn Chaiyakunapruk
Cultural beliefs, utility values, and health technology assessment. Cost effectiveness and resource allocation : C/E 16 (2018)
Rosarin Sruamsiri, Sameh Ferchichi, Aurélien Jamotte, Mondher Toumi, Hiroshi Kubo, Joerg Mahlich
Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach. Influenza and other respiratory viruses 11 (6) (2017)
Joerg Mahlich, K Matsuoka, Y Nakamura, R Sruamsiri
The relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in Japan. BMC public health 17 (1) (2017)
Joerg Mahlich, Isao Kamae, Rosarin Sruamsiri
Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment. Expert review of pharmacoeconomics & outcomes research 18 (3) (2017)
Stephane Cheung, Yukinobu Hamuro, Joerg Mahlich, Takanobu Nakahara, Rosarin Sruamsiri, Sunny Tsukazawa
Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis. Clinical drug investigation 37 (6) (2017)
Rosarin Sruamsiri, Yuko Kaneko, Joerg Mahlich
The underrated prevalence of depression in Japanese patients with rheumatoid arthritis - evidence from a Nationwide survey in Japan. BMC rheumatology 1 (2017)